and C-reactive protein. All-cause mortality at discharge, at 1 month and 3 months, alongside the length of hospital stay (LOS), were recorded. Results: In total, 315 patients were included, with 105 patients in each of the 3 groups. The mean age was 84.8 ± 5.5 years, with 41.9% males. All patients were followed up for 3 months. The percent all-cause mortality at discharge and the LOS for groups 1, 2 and 3 were 12.4, 3.8 and 8.6% and 11.2, 8.5 and 7.7 days, respectively. Group 1 had significantly increased mortality at 3 months [odds ratio (OR) 2.80, 95% confidence interval (CI) 1.12-6.96; p = 0.040] and LOS (OR 1.39, 95% CI 1.08-1.79; p = 0.008) compared to group 2 and did not differ significantly when compared to 3-month mortality (OR 2.39, 95% CI 0.91-6.29; p = 0.079) or LOS (OR 1.26, 95% CI 0.96-1.66; p = 0.097) in group 3. Conclusion: There is a significant association between an incidental rise in cTnI level with mortality and LOS in older patients. Further research is required to evaluate whether a more systematic management of these patients would improve the prognosis.
Introduction
Cardiac troponins (including cardiac troponin I, cTnI) are highly sensitive and specific biomarkers for myocardial injury [1] . Furthermore, in the patient who presents with an acute coronary syndrome (ACS), an elevated troponin level is associated with a poorer prognosis [2] . The prognosis of these patients in the absence of ACS is less certain, and in recent years, there has been increasing interest in quantifying the prognostic value of cTnI in this setting. Examples of this emerging role for cTnI include recent work showing that the cTnI assay is a useful independent predictor of mortality in patients hospitalised with severe pneumonia [3] and sepsis [4] , as well as in prognosticating the risk of long-term cardiac outcomes following acute stroke [5] .
The third universal definition of myocardial infarction (MI) [6] includes the category of type 2 MI, which is considered secondary to an ischaemic imbalance. In older patients, elevated cTnI levels are often seen where neither ACS nor another condition known to be associated with elevated cTnI levels is present [7, 8] . Equally, it is hard to demonstrate the presence of 'ischaemic imbalance' in these patients and hence define the rise in cTnI level as a 'type 2' MI. Given that in older patients the clinical presentation of ACS is often non-specific, greater reliance is placed upon the cTnI level by clinicians for diagnosis. What to do with this result is thus uncertain. Does this 'incidentally' raised troponin level mean that the patient should stay in hospital for longer as it may be of prognostic concern? Much of the research to date examining the prognostic value of elevated cTnI levels in the absence of ACS has focused on younger adults, and there remains a paucity of information about its prognostic impact on the older population [9, 10] . Of the limited research investigating this in older people, it is clear that an elevated cTnI level is associated with a poorer prognosis when compared to older people with ACS [11] . However, it remains unclear whether this also translates into a poorer prognosis when compared to hospitalised older people with normal cTnI levels and to what extent this might affect all-cause mortality and the length of hospital stay (LOS) in this group. We hypothesised that there is a significant association between an incidental rise in cTnI level and prognosis in older patients.
We aimed to investigate how all-cause mortality at hospital discharge, 1 month and 3 months was affected by the presence of an incidentally raised cTnI level in older patients when compared to older patients without an elevated cTnI level and to older patients diagnosed with ACS. Secondly, we aimed to investigate how LOS varied between these three groups.
Patients and Methods
This prospective, observational, matched cohort study investigated the prognosis of patients aged ≥ 75 years who attended the acute medical admissions unit (AMU) at a large university teaching hospital in the East of England (between April and June 2013).
Setting
The hospital covers a tertiary catchment population of up to 822,500 people (of mainly Caucasian ethnicity). Ethical approval for this study was gained from the Berkshire National Research Ethics Service (Research Ethics Committees reference: 12/LO/ 1744), and National Information Governance Board approval was gained from the Ethics and Confidentiality Committee, London.
Inclusion Criteria
All patients aged ≥ 75 years admitted to the AMU and who had a cTnI level measured at ≥ 8 h after symptom onset (for clinical reasons) were eligible for inclusion in this study. Patients were consecutively placed into 3 groups according to their cTnI result and underlying diagnosis. Patients in all 3 groups were matched by age (within 5 years) and week of admission. Patients who could not be matched were excluded. Patients with a cTnI level ≥ 0.04 μg/l according to the local reference laboratory values (Beckman Coulter assay, Access Immunoassay System, Beckman Coulter Inc., Fullerton, Calif., USA) and with no known cause attributable were included in group 1. These patients were referred to as having 'incidentally' elevated cTnI levels and were formally defined according to the third universal definition of MI as having type 2 MI [12] . Patients with a cTnI level <0.04 μg/l were included in group 2, and patients with a cTnI level ≥ 0.04 μg/l and diagnosed with ACS (according to the third universal definition of MI [12] ) were included in group 3 (see online supplementary Appendix 1; for all online suppl. material, see www. karger.com/doi/10.1159/000444083).
Exclusion Criteria
Patients <75 years of age were excluded from this study, as were any patients not admitted to the AMU or who did not have cTnI measured at ≥ 8 h after symptom onset. Patients meeting the inclusion criteria but who had an elevated cTnI level attributed to a cause other than ACS (as identified by the admitting clinical team), such as renal failure, pulmonary embolism, pericarditis, myocarditis, tachyarrhythmia, sepsis and critical illness, were also excluded.
Sample Size
The sample size was calculated with an expected in-hospital allcause mortality rate of 15% in the control and 30% in the case group based on the size of the expected effect from previous work [11] . In order to have 80% power at the 0.05 significance level, a minimum sample size of 95 patients per group was required for the primary outcome of in-hospital all-cause mortality.
Data Collection
A list of patients was obtained from a prospective registry of patients admitted to the AMU on a weekly basis, and any patient eligible for inclusion in the study had their hospital number recorded. Following this, each hospital number was entered into the hospital laboratory data system to check whether or not a cTnI level had been recorded. Two team members who were clinically qualified reviewed the clinical notes of each of the patients meeting the inclusion criteria and subsequently categorised them into 1 of the 3 groups based on clinical features, other investigation results and the diagnosis made by the admitting consultant (lead physician for the patient).
In addition to recording the cTnI levels, we also recorded age, sex, diagnosis, medical history, basic laboratory data, ECG findings, LOS and whether or not the patient was alive at discharge, 1 month and 3 months. The primary outcome measure was allcause mortality at hospital discharge, 1 month and 3 months, measured using the Patient Administration System [13] . The secondary outcome measure was in-patient LOS.
Statistical Analysis
Comparisons were made between patients in group 1 with sexand age-matched (±5 years) patients in groups 2 and 3. Potential risk factors and outcomes were compared between the groups using mixed-effects regression models, where the fixed effect was the group and the random effect was the matching pair. This accounted for the clustering of individuals by matched pair and makes the standard assumption of independence invalid. The potential risk factors were compared using a linear mixed-effects model without any further adjustment. Mortality outcomes were analysed using a logistic mixed-effects regression model and LOS by a linear mixed effect. Sensitivity analysis adjusted for a past medical history of cardiovascular heart disease (defined as the presence of heart failure, hypertension, ischaemic heart disease, MI, valvular Data given are n (%), or the mean ± SD. WBC = White blood cell count. a Age and sex were used as the matching criteria between groups 1 -3, and, thus, no significant differences were present. b p value corresponds to the comparison between group 1 and group 3. Group 2 were age-and sex-matched controls that had normal cTnI levels (i.e. <0.04 μg).
c Cardiovascular heart disease defined as previous medical history including the presence of any of permanent pacemaker, heart failure, hypertension, ischaemic heart disease, MI or valvular heart disease.
d Coronary heart disease defined as previous medical history including the presence of either ischaemic heart disease or MI. e Six participants with both ischaemic heart disease and MI.
heart disease or a permanent pacemaker). We also included adjustment for renal function (estimated glomerular filtration rate, eGFR) and C-reactive protein (CRP) as continuous risk factors by including them as a linear predictor in the model.
Results

Patient Characteristics
In total, 315 patients (105 patients in each group) who met the eligibility criteria were included. The sample mean age was 84.8 ± 5.5 years, and 41.9% were men. The sample characteristics are shown in table 1 . At baseline, CRP was higher in group 1 compared to groups 2 and 3 (p = 0.0001). Although eGFR was lower in group 1 compared to groups 2 and 3 (p = 0.0085), the mean eGFR in all groups was within the criteria of chronic kidney disease stage 3. The total length of follow-up was 3 months from the date of index admission for each patient. The overall all-cause mortality at hospital discharge was 8.3%, which rose to 10.8% by the end of 1 month and was 14.9% by the end of the 3-month period. The mean LOS was 9.1 days. None of the patients were lost to follow-up.
Association between the cTnI Group and All-Cause Mortality
Analysis of all-cause mortality between patients in groups 1 and 2 demonstrated that those with an incidentally raised cTnI level (group 1) were almost three times more likely to die at 3 months [odds ratio (OR) 2.81, 95% confidence interval (CI) 1.05-7.50; p = 0.04] compared to their counterparts in group 2, after adjustment for cardiovascular medical history, CRP and renal function. Group 1 also had a statistically significant increase in all-cause mortality whilst being an in-patient (p = 0.027) and at 1 month following discharge (p = 0.013) compared to group 2 in the unadjusted analysis. However, on adjustment for cardiovascular medical history, CRP and renal function, this difference became non-significant (p = 0.089 and p = 0.091, respectively; table 2 ). Analysis of all-cause mortality between patients in groups 1 and 3 revealed no statistically significant differences in all-cause mortality time points in the adjusted model ( table 3 ) at discharge (p = 0.585), at 1 month (p = 0.379) and at 3 months (p = 0.079). There were also no statistically significant differences in all-cause mortality time points between groups 2 and 3; the corresponding p values were 0.16, 0.30 and 0.49 in the adjusted model, respectively.
Association between the cTnI Group and LOS Group 1 had a significantly prolonged LOS compared with group 2 (OR 1.50, 95% CI 1.11-2.03; p = 0.008) when adjusted for cardiovascular medical history, CRP and renal function with almost three additional hospitalised inpatient days on average ( table 2 ) . There were no statistically significant differences in LOS between groups 2 and 3 in the adjusted model (p = 0.08), or between groups 1 and 3 (p = 0.097; table 3 ).
Discussion
Our findings show that older patients with incidentally elevated cTnI levels have a poorer prognosis than age-and sex-matched patients with cTnI <0.04 μg/l. Although the prognostic significance of cTnI has been previously documented [14] , we present the first data focusing on the older population with or without elevated incidental cTnI levels compared to ACS patients, and our results suggest a role of cTnI as a biomarker for adverse prognosis and longer hospital stay in this age group.
To date, there have been little data on the ideal management of patients with incidentally elevated cTnI levels, and there are no randomised controlled trials investigating strategies to improve both immediate and long-term mortality and other important outcomes, such as LOS and quality of life. In particular, uncertainty continues to exist regarding whether there is benefit in optimising the cardiac medications of these patients and the exact role of angiotensin-converting enzyme inhibitors, β-blockers, statins, nitrates, low-dose aspirin or other secondary prevention medication for incidentally raised cTnI levels [15, 16] . The third universal definition of MI [6] introduced type 2 MI, in which the underlying pathophysiology is due to micronecrosis of cardiac myocytes precipitated by a primary imbalance in the myocardial blood supply to myocardial oxygen demand ratio. Studies of cardiac angiographic correlation in relation to type 1 and type 2 MI have shown that the majority of type 2 MIs do not have clear underlying coronary vessel disease [17] . Thus, given that a raised troponin level in itself is not a marker of a ruptured plaque (type 1 MI) but rather one of downstream micronecrosis, patients with an incidentally elevated cTnI level do not necessarily need to proceed to coronary angiography with a view to revascularisation. However, in this older population (and indeed in younger ones), it is hard to prove the presence of 'ischaemic imbalance'. How does, for instance, a clinician make an assessment of coronary endothelial dysfunction in their 85-year-old with an inciIncidentally Raised Troponin I Worsens Prognosis Gerontology 2016;62:581-587 DOI: 10.1159/000444083 585 dentally raised troponin level? With the latest-generation high-sensitivity troponin testing, knowing what to do with the increasing incidence of an unexpected troponinpositive test will be even harder [18] .
Further ambiguity persists regarding the ideal environment for the care of these hospitalised patients and whether they should be managed by cardiologists, or by geriatricians/general physicians. We propose that these patients do not comfortably fit into any category under the third definition of MI. The exact role of cTnI may not be solely a diagnostic one but more akin to that of an independent biomarker of general physiological frailty or co-morbidity severity [14] . Whether it should be formally incorporated into existing prognostic scoring systems used in other conditions such pneumonia [19, 20] , stroke [21, 22] and for acutely unwell older patients remains unknown [23] . Such increases in troponin levels may, however, simply point to underlying poor health that is not directly reflected in indices such as the pre-morbid Rankin score, which measures disability and dependence. This is supported by the fact that although the pre-morbid Rankin score was higher in group 1, especially when compared with ACS patients in group 3 (2.12 vs. 1.69; p = 0.0027), additional adjustment for it did not change our results (see online suppl. tables 1 and 2).
In addition to the clear difference in all-cause mortality rates between patients with incidentally raised cTnI levels and age-and sex-matched patients with a normal cTnI level, the fiscal implications from prolonged LOS are also considerable. During the 3-month period of this study, 105 Table 2 . Risk of all-cause death in patients with incidentally raised cTnI levels (group 1) compared to age-and sex-matched controls without raised cTnI levels (group 2) Data given are n (%), unless otherwise indicated. 1 Adjusted for the presence of a past medical history of cardiovascular heart disease (defined as the presence of either heart failure, hypertension, ischaemic heart disease, MI, valvular heart disease or a permanent pacemaker), renal function (eGFR) and CRP as continuous variables (see Patients and Methods section). Data given are n (%), unless otherwise indicated. 1 Adjusted for the presence of a past medical history of cardiovascular heart disease (defined as the presence of either heart failure, hypertension, ischaemic heart disease, MI, valvular heart disease or a permanent pacemaker), renal function (eGFR) and CRP as continuous variables (see Patients and Methods section). patients with incidentally raised cTnI levels stayed approximately 3 additional days in hospital compared to patients with a normal cTnI level. If extrapolated over a single year, we estimate that older patients with incidentally elevated cTnI levels may result in over GBP 350,000 in additional costs from prolonged hospital stay [24] . Given that these results are based on a single hospital with a catchment population of <1.0 million, the potential health economic impact in the UK and also globally is substantial. This emphasises the need for further work to better understand this disease entity and to address the uncertainties regarding its optimal management highlighted above.
Limitations
As a hospital-based study, troponin measurements were made after presentation to hospital, which might have introduced some bias towards attenuation of the effect size. Nonetheless, random measurement error is less important as we were interested in discrete well-characterised clinical syndromes rather than in troponin I rise and outcome. With recent advances in high-sensitivity laboratory assays, more minute increases in cTnI levels can now be accurately measured; however, their exact significance continues to be the source of much interest [25] . We were limited by the diagnostic accuracy of the cTnI assay available in our laboratory ( ≥ 0.04 μg/l) at the time of the study, but evidence is emerging that in older patients, even very low levels of cTnI may be associated with a higher mortality [26] . As a result, it is possible that there were patients with small incidental elevations in cTnI levels that were undetected but may have attenuated the differences among the groups.
We did not have detailed information on cardiac angiography results as the cases (group 1) are usually managed by general physicians or are under the care of the elderly specialists who may not feel that interventional cardiology is warranted in these individual patients. Furthermore, we could not stratify our patients by type of ACS, which could have provided finer granularity of the real impact of incidental rise compared to specific ACS syndromes. All patients with a cTnI measured (for clinical reasons) were included in this study. Since we could not randomise which patients had their cTnI measured, it is possible that an element of selection bias was present within our cohort. This, however, will not have impacted on the internal relationship between exposure and outcome in the population of interest. We also noted lower mortality rates than those previously reported in the published literature upon which our sample size calculation was based [10] . This may be due to the fact that there have been many changes in service efficiency since these previous reports have been published. As with any sample size calculation, it was based on the best available evidence for estimation and will, however, only further attenuate the results.
Conclusion
Incidental rises in cTnI levels are common amongst the older population presenting to hospital. This study has shown that there is a strong association between incidental rise in cTnI level and poor prognosis in older patients. Further research is needed to explore whether more invasive investigation and/or treatment are indeed clinically effective and cost effective in managing older patients with an incidental rise in cTnI level. This is particularly salient in the coming years when this older age group will make up an increasing proportion of presentations to AMU.
